NCT03121963

Brief Summary

Our study aims to see if the addition of a scheduled non-opioid pain regimen will decrease the use and risk of opioid pain medications as well as improve pain control in head and neck surgery patients. Participants will be randomized to one of two pain regimens (opioid medication regimen vs combination regimen of opioid and non-opioid medications).

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Nov 2017

Longer than P75 for phase_4

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 17, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 20, 2017

Completed
7 months until next milestone

Study Start

First participant enrolled

November 10, 2017

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 6, 2020

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

November 6, 2021

Completed
Last Updated

June 22, 2021

Status Verified

June 1, 2021

Enrollment Period

3 years

First QC Date

April 17, 2017

Last Update Submit

June 17, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Participant pain control

    Self-report via questionnaire of pain score, pain improvement, average pain, location of pain, and interference with daily activities

    2 weeks

Secondary Outcomes (1)

  • Opioid medication use

    2 weeks

Study Arms (2)

Treatment Group

EXPERIMENTAL

A combination regimen of oxycodone 5 mg Q6hr PRN, acetaminophen 650 mg Q6hr, celecoxib 400 mg BID post-operatively x 2 weeks, and gabapentin 400 mg loading dose, 300 mg TID to be started 1 week pre-operatively then continued post-operatively x 2 weeks.

Drug: OxycodoneDrug: AcetaminophenDrug: GabapentinDrug: Celecoxib

Control Group

ACTIVE COMPARATOR

A single medication regimen of hydrocodone-acetaminophen 7.5 mg Q6hr PRN post-operatively x 2 weeks.

Drug: Hydrocodone-Acetaminophen

Interventions

oxycodone tablet

Also known as: Oxycontin
Treatment Group

acetaminophen tablet

Also known as: Tylenol
Treatment Group

gabapentin tablet

Also known as: Neurontin
Treatment Group

celecoxib tablet

Also known as: Celebrex
Treatment Group

hydrocodone 5 mg/acetaminophen 325 mg tablet

Also known as: Norco
Control Group

Eligibility Criteria

Age18 Years - 69 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age 18-69
  • able to consent for themselves
  • undergoing a "moderate" head and neck surgery at UAB, defined as procedures that generally require only 1-2 night stay in the hospital. For the purposes of this protocol, this will include patients undergoing neck dissections, glossectomy with primary closure, thyroidectomy, or parotidectomy

You may not qualify if:

  • age \< 18 or \> 69
  • unable to consent for themselves
  • have a known opioid tolerance or are one a home opioid regimen prior to surgery
  • known hepatic failure, renal failure, or sulfa allergy, as determined by standard of care labs drawn within 30 days of enrollment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Agnosia

Interventions

OxycodoneAcetaminophenGabapentinCelecoxiboxycodone-acetaminophen

Condition Hierarchy (Ancestors)

Perceptual DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

CodeineMorphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic CompoundsAcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesgamma-Aminobutyric AcidAminobutyratesButyratesAcids, AcyclicCarboxylic AcidsCyclohexanecarboxylic AcidsAcids, CarbocyclicCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsAmino AcidsAmino Acids, Peptides, and ProteinsBenzenesulfonamidesSulfonamidesBenzene DerivativesHydrocarbons, AromaticSulfonesSulfur CompoundsPyrazolesAzolesHeterocyclic Compounds, 1-Ring

Study Officials

  • Erin Partington Buczek, MD

    University of Alabama at Birmingham

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 17, 2017

First Posted

April 20, 2017

Study Start

November 10, 2017

Primary Completion

November 6, 2020

Study Completion

November 6, 2021

Last Updated

June 22, 2021

Record last verified: 2021-06

Data Sharing

IPD Sharing
Will not share

There is no current plan to share individual participant data for this protocol.